




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 11% points. The greatest weakness of PUMA Biotechnology INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 174% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 97% points below the market average of 238%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	166,296	Assets	234,905
Cost of Goods Sold	0	Liabilities	217,442
Intangible Assets	0	Expenses	311,358
Liabilities, Current	90,837	Revenues	272,260
Liabilities, Non-Current	22,643	Stockholders Equity	17,463
Other Assets	65,305	Net Income	-75,595
Other Compr. Net Income	74	Comprehensive Net Income	-75,558
Other Expenses	36,815	BaseVar	536,268
Other Liabilities	103,962	ECR before LimitedLiability	-17%
Other Net Income	-36,497	Economic Capital Ratio	141%
Other Revenues	272,260		
Property and Equipment	3,304		
Research and Development	132,851		
Selling, General and Administrative Expense	141,692		